ClinicalTrials.gg
CompletedNCT07694128Updated Jul 9, 2026

Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets

A Phase 1 interventional study of Selexipag Film Coated Tablets (T1) and Selexipag Film Coated Tablets (T2) in Arterial Hypertension (PAH), sponsored by Humanis Saglık Anonim Sirketi. Completed at 1 site in India. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Humanis Saglık Anonim Sirketi · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Hypertension with a site in India — 8 open to participants now, 13 under way, 7 of them phase 3. Hypertension · India.

Enrollment
52nd of 59
30 · median 422
Started
2026
with 2 others
Phase 1
6 of 67
none open now
Registered
67th of 67
by date

Among the 67 studies in Hypertension with a site in India, this one is the 52nd largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 1, and was the 67th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

8 of the 67 studies in Hypertension with a site in India are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Hypertension with a site in India, or all of them as a file.
02

Study summary

An open label, randomized, Three treatment, Three sequence, Three period, Three way crossover, single dose oral bioequivalence study to compare Selexipag 400 microgram film coated tablets versus Uptravi® (selexipag) 400 microgram film coated tablets in fed condition.

03

Conditions studied

  • Arterial Hypertension (PAH)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged between 18 to 55 years (both inclusive).
  • Participants' weight within normal range according to normal values for (between 18.50 to 30.00 kg/m2) (both inclusive) with minimum of 45 kg weight.
  • Participants with normal health as determined by personal medical history, clinical examination and laboratory examinations within Predefined site Normal range [Annexure III].
  • Participants having clinically acceptable 12-lead (ECG).
  • Participants having clinically acceptable chest X-Ray (PA view), if taken.
  • Participants having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine and morphine).
  • Participants having negative urine alcohol test / breath alcohol test.
  • Non-smoker.
  • Participants willing to adhere to the protocol requirements and to provide written .
  • For Male Participants: Participants willing to follow approved methods (a double barrier method) for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide, Condom with diaphragm, or abstinence. Participants willing to refrain from donating sperm during the study period
  • For Female Participants: Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), abstinence, bilateral tubal ligation or double barrier contraception, i.e., condom + diaphragm, condom + spermicidal or foam or for at least 1 year, or if less than 1 year, then following acceptable contraceptive measures as mentioned above
  • Participants having negative urine pregnancy test at screening and negative serum beta-hCG pregnancy test on admission day of period 01 (only for female Participants).

Exclusion criteria

Exclusion Criteria:

  • to Selexipag or ondansetron, paracetamol, or related class of drugs or any of its .
  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.
  • Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to admission in period 01.
  • Presence of alcoholism or drug abuse.
  • History or presence of asthma, urticaria or other significant allergic reactions.
  • History or presence of significant gastric and/or duodenal ulceration.
  • History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
  • History or presence of serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including SSRIs and SNRIs).
  • History or presence of cancer or basal or squamous cell carcinoma.
  • Difficulty with donating blood.
  • Difficulty in swallowing solids dosage form like tablets or capsules.
  • Use of any prescribed medication or OTC medication including vaccines, vitamins and herbal remedies during last 30 days prior to admission in period 01.
  • Major illness within past 3 months.
  • Participant who have donated blood (1 unit) or participation in a drug research study within past 90 days prior to the first dose of the study drug.
  • Consumption of xanthine-containing foods or beverages (like chocolate, tea, coffee or cola drinks), tobacco containing products or alcohol or any alcohol containing products within 48.00 hours prior to admission in period 01.
  • Consumption of grapefruit or grapefruit juice containing products within 72.00 hours prior to admission of period 01.
  • Positive screening test for any one or more: , and .
  • History or presence of significant easy bruising or bleeding.
  • History or presence of significant recent trauma.
  • Participants who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.
  • Female Participants who are currently breast feeding.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Selexipag film coated tablets (T1)

    Selexipag 400 microgram film coated tablets

    Drug: Selexipag Film Coated Tablets (T1) · Drug: Selexipag Film Coated Tablets (T2) · Drug: Uptravi® (selexipag) film coated tablets

  • Experimental
    Selexipag film coated tablets (T2)

    Selexipag 400 microgram film coated tablets

    Drug: Selexipag Film Coated Tablets (T1) · Drug: Selexipag Film Coated Tablets (T2) · Drug: Uptravi® (selexipag) film coated tablets

  • Active comparator
    Uptravi® (selexipag) film coated tablets

    Uptravi® (selexipag) 400 microgram film coated tablets

    Drug: Selexipag Film Coated Tablets (T1) · Drug: Selexipag Film Coated Tablets (T2) · Drug: Uptravi® (selexipag) film coated tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum concentration obtained (Cmax)

    two-sides 90% CI for the test to reference ratio of the population means is within 80.00-125.00% for each of the Ln-transformed data Cmax

    Time frame: 20 hours

  2. AUC from time 0 to last collection time (AUC0 - t)

    two-sides 90% CI for the test to reference ratio of the population means is within 80.00-125.00% for each of the Ln-transformed data AUC

    Time frame: 20 hours

Secondary outcomes

  1. Time to reach maximum concentration Cmax (Tmax)

    Descriptive Statistics

    Time frame: 20 hours

  2. Area Under the Curve from time zero to time infinite (AUC0-infinite)

    Descriptive Statistics

    Time frame: 20 hours

07

Study locations

1 site
  • Veeda Clinical Research Ltd.
    Ahmedabad, Gujarat 380 015, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Jun 2026, 2 months.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 2 months is close to that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2026
First posted
Jul 9, 2026
StartActual
Apr 8, 2026
Primary completionActual
Jun 16, 2026
CompletionActual
Jun 22, 2026
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07694128
Responsible party
Sponsor
First posted
Jul 9, 2026
Start date
Apr 8, 2026
Primary completion
Jun 16, 2026
Completion
Jun 22, 2026
Last update
Jul 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selexipag

Start the discussion